← All trials
NCT04756323
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 27, 2020
- Primary completion
- Jun 30, 2021
- Completion date
- Feb 28, 2022
- First posted
- Feb 16, 2021
- Last posted
- Feb 17, 2021
- Enrollment
- 1000
- Arms / groups
- 12 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Beijing Minhai Biotechnology Co., LtdLead sponsor
- Government of ChinaCollaborator
- Shenzhen Kangtai Biological Products Co., LTDCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.